Additionally, the changes in blood sugar levels the drug prompts could impact hormone production, potentially reducing collagen
There are six GLP-1-based medicines currently approved by the US Food and Drug Administration (FDA): exenatide, lixisenatide, liraglutide, semaglutide, dulaglutide and albiglutide (Table 1)
Learn more about the summit, and register here: #GLP1Summit #GLP1 #PrescriptionTrends #PrescribingTrends #PrescriptionData #Tirzepatide #Semaglutide #EHRData #ClinicalExpertLedAI #MedicalAI #HealthAI #HealthcareAI #AI #Innovation #RealWorldData #RWD
With regard to exposure, more rapid dose escalation or greater overall exposure may increase gastrointestinal symptom burden (72), thereby promoting avoidance of specific foods (78) and increasing the likelihood of related complaints
It activates three key hormone receptors involved in metabolic health: Reduces appetite, improves insulin sensitivity Supports insulin release and metabolic balance Increases energy expenditure, promotes fat breakdown This triple-agonist approach is designed to produce greater and faster weight loss than all other therapies